Gripmax® Nose Child effectiveness in the upper respiratory tract infections treatment

Children are highly predisposed to the respiratory tract infections. Nowadays, attention unit has been focused on the effect of herbal therapy on respiratory tract infections treatment.

Objective. To assess Gripmax® Nose Child effectiveness in patients with rhinitis.

Materials and methods. The open multicentral observational study of safety and effectiveness of the biologically active additive Gripmax® Nose Child. Data collection was performed in various regions of Russia (March–September 2023) via medical records analysis by ambulatory doctors followed by making a special individual registration form. Symptoms were assessed initially (visit 1), after 2–3 days (telephone contact), after 6–7 days (visit 2), after 10–14 days (visit 3). Duration of herbal treatment varied from 7 to 14 days.

Results. Ambulatory medical records of 1073 children aged 3–18 with rhinitis received Gripmax® Nose Child and additional therapy if needed was analyzed. If Gripmax® Nose Child was added to complex therapy, general condition improved, nasal obstruction and secretion significantly reduced from day 2–3. Patients demonstrated statistically significant (p<0,0001) rhinitis symptoms decrease (redness, nasal obstruction and rhinorrhea decrease up to vanishing in 84% by visit 2 and in 99% by visit 3, and up to 96.5% of patients at the treatment course end.

Conclusion. Investigated herbal therapy including herbal components may be recommended as an effective for rhinitis therapy.